Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 5/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 5/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30795826 | 0.85 | FFAR1 (0.46) | FFAR1MEN1KMT2ASMN1; SMN2HTT | |
| SCHEMBL2070719 | 0.85 | FFAR1 (0.46) | FFAR1MEN1KMT2ASMN1; SMN2HTT | |
| SCHEMBL30795486 | 0.83 | FFAR1 (0.44) | FFAR1SMN1; SMN2HTTMAPTNPC1 | |
| SCHEMBL3112428 | 0.83 | FFAR1 (0.44) | FFAR1SMN1; SMN2HTTMAPTNPC1 | |
| SCHEMBL4995871 | 0.82 | LMNA (0.45) | FFAR1MEN1KMT2APKMHTT | |
| SCHEMBL30814210 | 0.74 | MAPK1 (0.38) | PKMHTTMAPTALDH1A1MAPK1 | |
| SCHEMBL3109667 | 0.74 | MAPK1 (0.38) | PKMHTTMAPTALDH1A1MAPK1 | |
| SCHEMBL4993177 | 0.73 | HTT (0.47) | MEN1KMT2ASMN1; SMN2PKMHTT | |
| SCHEMBL4996561 | 0.72 | MEN1 (0.46) | MEN1KMT2ASMN1; SMN2HTTALDH1A1 | |
| SCHEMBL2070657 | 0.72 | FFAR1 (0.47) | FFAR1HTTMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7368472-B2 | 1,2,4-Triaminobenzene derivatives useful for treating disorders of the central nervous system | H. LUNDBECK A/S (DK) | 2008-05-06 | — | — | US | disclosed |
| EP-1578740-B1 | 1,2,4-TRIAMINOBENZENE DERIVATIVES USEFUL FOR TREATING DISORDERS OF THE CENTRAL NERVOUS SYSTEM | LUNDBECK & CO AS H (DK) | 2007-03-21 | — | — | EP | disclosed |
| US-20060014822-A1 | 1,2,4-Triaminobenzene derivatives useful for treating disorders of the central nervous system | H. LUNDBECK A/S (DK) | 2006-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014822-A1 | 1,2,4-Triaminobenzene derivatives useful for treating disorders of the central nervous system | PMP22, GRIN2B, AVPR1B | FFAR1 2339/4885MEN1 1105/4885KMT2A 2295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.